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OBJECTIVE—To determine the effect of metformin on the acute metabolic response to sub-
maximalexercise,the effect of exercise on plasma metformin concentrations, and the interaction
between metformin and exercise on the subsequent response to a standardized meal.
RESEARCH DESIGN AND METHODS—Ten participants with type 2 diabetes were
recruited for this randomized crossover study. Metformin or placebo was given for 28 days,
followedbythealternate conditionfor 28days.Onthelast2days ofeachcondition,participants
were assessed during a nonexercise and a subsequent exercise day. Exercise took place in the
morning and involved a total of 35 min performed at three different submaximal intensities.
RESULTS—Metforminincreasedheartrateandplasmalactateduringexercise(bothP#0.01)
but lowered respiratory exchange ratio (P = 0.03) without affecting total energy expenditure,
whichsuggestsincreasedfatoxidation.Metforminplasmaconcentrationsweregreateratseveral,
but not all, time points on the exercise day compared with the nonexercise day. The glycemic
response to a standardized meal was reduced by metformin, but the reduction was attenuated
when exercise was added (metformin 3 exercise interaction, P = 0.05). Glucagon levels were
highest in the combined exercise and metformin condition.
CONCLUSIONS—This study reveals several ways by which metformin and exercise thera-
pies can affect each other. By increasing heart rate, metformin could lead to the prescription of
lowerexercise workloads.Furthermore,underthetestedconditions,exerciseinterferedwiththe
glucose-lowering effect of metformin.
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I
t is estimated that there were over 42
million prescriptions for metformin
in the U.S. in 2009 (top 10 for generic
drugs) (1). Along with these prescrip-
tions, exercise had likely been recom-
mended to most of these patients since
metformin therapy andlifestylemodiﬁca-
tions are considered the ﬁrst step for the
management of type 2 diabetes (2).
Despite the vast literature examining
the effects of metformin or exercise sep-
arately, surprisingly few studies have ex-
amined how they affect each other, or if
theircombinationoffersadditivebeneﬁts.
There is some evidence suggesting that
thebeneﬁts ofexercise andmetforminare
not additive. For example, in the Indian
Diabetes Prevention Program, reductions
in the risk of diabetes were similar in the
combined metformin and lifestyle modi-
ﬁcation group (228.2%) compared with
the metformin (226.4%) or lifestyle
alone (228.5%) groups (3). In addition,
metformin has been recently suggested
to attenuate the insulin-sensitizing effect
of exercise (4).
Muscle contraction is known to re-
sult in the metabolic conditions that lead
to activation of AMP-activated protein
kinase (AMPK), and there is growing
evidence that metformin also increases
AMPK activity in liver, muscle, and other
tissues(5).Recently,therehasbeenmuch
attention given to AMPK activators as
exercise mimetics (6) and metformin has
beenshowntoimproveexercisetolerance
in nondiabetic women with clinically de-
ﬁned angina (7).
The objectives of the current explor-
atory study were threefold: 1)t oe x a m i n e
the effect of metformin on the acute met-
abolic and hormonal responses to exer-
cise, 2) to examine the effect of exercise
onplasmametforminconcentrations,and
3) to examine the interaction between
metformin and acute exercise on the sub-
sequent response to a standardized meal.
RESEARCH DESIGN AND
METHODS
Participants
Ten volunteers (eight men and two post-
menopausal women) with type 2 diabetes
were recruited for this study, which was
approved by the University Health Re-
search Ethics Board. Participants met the
following eligibility criteria: 1) between
30 and 65 years of age; 2)n o tt a k i n g
glucose-lowering medication or insulin;
3) no changes in physical activity over
the last 3 months and not planning on
changing medication, physical activity,
or diet over the course of the study; and
4)H b A 1c #8%, resting blood pressure
#140/90 mmHg, LDL cholesterol #3.5
mmol/L, and total:HDL cholesterol #5.0.
Study design
Thestudyusedafactorialdesignandeach
participant was exposed to 4 conditions:
1) metformin and no exercise, 2)m e t f o r -
min and exercise, 3)p l a c e b oa n dn oe x -
ercise, and 4) placebo and exercise. The
order of the metformin versus placebo
conditions was randomized by personnel
not involved with the study, and alloca-
tion was concealed in sealed envelopes
until participants completed the study.
Participants, study personnel, and inves-
tigators were blinded to the order of the
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ORIGINAL ARTICLEplacebo/metformin conditions. Metfor-
min or placebo was given for 28 days,
immediately followed by the alternate
condition for 28 days. On the last 2 days
of each condition (days 27 and 28), par-
ticipants returned to the Exercise Physi-
ology Laboratory for a nonexercise and
exercise session, respectively. The order
of these sessions was not randomly deter-
mined.Exercisewasalwaysperformedon
day 28 since the acute glucose-lowering
effect of exercise may persist for at least
24 h (8).
Study protocol
During the baseline, an exercise stress
test with a 12-lead electrocardiogram was
performed using a modiﬁed Balke-Ware
treadmill protocol. Each participant
walked at a self-selected speed, deter-
mined as comfortable but fast, while the
grade was increased by 2% each minute.
The test was ended when the participant
could no longer continue. This protocol
was used to determine the peak oxygen
uptake (VO2peak) and ventilatory thresh-
old using the V-slope method.
After the baseline visit, participants
were given either metformin or placebo
pills and were asked to maintain their
routine physical activity and dietary hab-
its. Each participant consumed 500 mg
of metformin with breakfast during the
ﬁrst week of the intervention followed by
a 500-mg increase in each of the subse-
quent weeks until 1,000 mg were con-
sumed with breakfast and supper during
week 4 (total: 2,000 mg/day).
On days 27 and 28 of the metformin
and placebo conditions, participants ar-
rived in the laboratory at 8:00 A.M. after a
12-h fast. Fasting glucose was measured
with a handheld glucose meter (One
Touch Ultra; LifeScan, Milpitas, CA),
and then participants ate a standardized
breakfast (549 kcal; 56% carbohydrate,
30% fat, 14% protein) and took their as-
signed pills. At 10:00 A.M., an intravenous
catheter was inserted into an antecubital
vein kept patent with 0.9% sterile saline
andtheﬁrstbloodsamplewascollectedat
10:20 A.M. On day 27 of the metformin
and placebo conditions, the participants
remained at rest for the duration of the
testing period. At 10:45 A.M. of day 28
during both conditions, participants
performed a series of exercises that were
selected to represent different intensities,
modes, and energy systems. They began
with 20 consecutive maximal leg exten-
sionsandﬂexionsonaCybexIIisokinetic
dynamometer (Lumex). The isokinetic
test was included sinceresistance exercise
is recommended for people with diabetes
(9) and since isokinetic testing helps
avoid eccentric contractions under load,
which might induce muscle damage and
impact the subsequent treadmill tests.
The angular velocity was set at 180° 3 s
21
(3.14 rads 3 s
21), and measurements of
peak torque, mean torque, and a fatigue
index were calculated. After a 5-min rest
period, the ﬁrst of three aerobic exercise
boutsbegan.Eachboutwasseparatedbya
5-min rest period during which blood
samples were drawn from the catheter.
During the ﬁrst exercise bout, all partici-
pants walked at 3.5 km/h and 0% grade
for 15 min. This corresponded to the esti-
mated average walking speed for individ-
uals with type 2 diabetes in free-living
conditions(10).Thesecondboutalsolasted
15 min and was completed at a speed and
grade equivalent to an intensity below
each participant’s measured ventilatory
threshold. The third bout was completed
at an intensity above their ventilatory
threshold and lasted 5 min.
Metabolic outcomes such as the vol-
ume of oxygen consumed (VO2) and the
volume of carbon dioxide produced
(VCO2) during exercise were measured
with a TrueMax metabolic measurement
system (Parvo Medics, Salt Lake City,
UTtah). Heart rate (HR) was measured
using a Polar heart rate monitor (Polar
Electric, Finland), and rate of perceived
exertion was estimated with the Borg
Scale.
About 20 min after exercise (at 11:59
A.M.), another blood sample was taken
immediately before the standardized
meal (556 kcal; 59% carbohydrate, 22%
fat, 19% protein). Participants remained
inthelaboratory,andbloodsampleswere
taken every 30 min for 2 h.
Each blood sample was ﬁrst trans-
ferred into a 10-mL EDTA vacutainer
tube.Subsequently,0.25mLwholeblood
was transferred into 1.0 mL ice-cold
8% perchloric acid, and 2.0 mL was
transferred into a tube with 67 mL
aprotinin. Perchloric acid was added for
deproteinization as required for the lac-
tate analysis. Aprotinin was added to
eliminate proteases known to interfere
with the determination of glucagon.
Tubeswerecentrifugedandcooledbefore
being moved to a 220°C freezer until
assays were completed. Serum lactate,
glucose, and nonesteriﬁed fatty acids
(NEFAs) were determined enzymatically
with spectrophotometric assays. Gluca-
gon and insulin were measured using
commercially available radioimmunoassay
(RIA) kits (Millipore, St. Charles, MO
and Inter Medico, Markham, Ontario,
Canada, respectively). All assays were
r u ni nd u p l i c a t e .
Plasma metformin concentrations
were assessed in all plasma samples by
a high performance liquid chromato-
graphic. The concentration of phosphate
solution used in the mobile phase was
20 mmol/L. The assay was validated to a
lower limit of quantitation of 7.8 ng/mL
metformin based on 0.1 mL of human
plasma (11).
Potential confounding variables
Participants completed a 24-h food recall
for the day preceeding each testing ses-
sion. These were analyzed for calorie and
macronutrient content using Food Pro-
cessor SQL (Version 8.3.0; ESHA Re-
search, Salem, OR). Habitual physical
activity during each 4-week intervention
was assessed using the Godin Leisure
Time questionnaire (12). Finally, partici-
pants were asked to indicate their percep-
tion of which intervention (metformin or
placebo) they had just completed on a
150-mm visual analog scales as well as
symptoms such as nausea, headache, ﬂat-
ulence, abdominal discomfort, and in-
digestion.
Statistical analyses
Analyses were conducted using repeated-
measures ANOVA with treatment order
added as a between-subject factor. To
simplify the interpretation, the testing
dayswerebrokendownintofourperiods:
pre-exercise, exercise, postexercise, and
postlunch. The number of within-factors
and levels varied among these periods
(e.g., postlunch was a 2 3 2 3 4 factorial
ANOVA to examine the effect of exercise,
metformin, and time, respectively). Insu-
lin,glucagon,glucose,lactate,andNEFAs
werelogtransformed beforethe statistical
analyses to favor normality of residuals
and homogeneity of variance. The non-
transformed mean 6 standard deviations
data are presented. Statistical tests were
two-tailed, and P values of #0.05 were
considered signiﬁcant. Statistical analyses
were performed with SPSS 18 (SPSS Inc.,
Chicago, IL).
RESULTS—Baseline characteristics are
presented in Table 1. Some reported mild
to moderate gastrointestinal side effects
during the metformin intervention; but
all participants except one (ﬁnal metfor-
min dosage, 1,500 mg/day) were able to
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Metformin and exercisetolerate the maximum dosage of 2,000
mg/day during the last week of the inter-
vention. Half of the participants started
with 28 days of metformin.
Oxygen consumption (VO2), respira-
tory exchange ratio (RER), HR, and rating
of perceived exertion (RPE) during exer-
cise are shown in Table 2. There was a
main effect of exercise intensity (all P #
0.01) and no interaction effect (all P $
0.18)forVO2,RER,HR,andRPE.Theﬁrst
15-min bout was performed at 33.9 6
5.4% of VO2peak, the second 15-min
bout averaged 67.2 6 7.3% of VO2peak,
and the third 5-min bout averaged
79.4 6 8.8% of VO2peak. VO2 was not
affected by metformin (P = 0.60). How-
ever, mean RER was lower in the met-
formin condition (0.96 6 0.02 vs.
0.98 6 0.02; P =0 . 0 3 ) .M e a nH Rw a s
signiﬁcantly higher in the metformin
condition (124 6 9 vs. 118 6 8b e a t s
per minute [bpm]; P = 0.009). The
mean subjective ratings of perceived ex-
ertion during exercise were similar in the
metformin and placebo conditions. How-
ever, participants reported a higher per-
ceived exertion on their ﬁrst exercise day
regardless of whether they were on met-
formin or placebo. As well, when con-
sidering treatment order in the analyses,
RPE was higher in the metformin condi-
tion (P = 0.03).
Plasma metformin concentrations
Plasma metformin concentrations were
higher onthe exercise daycomparedwith
the nonexercise day 25 min before exer-
cise (1,8976352vs.1,594 6363ng/mL;
P = 0.02) and 20 min after exercise
(2,230 6 335 vs. 1,893 6 323 ng/mL;
P = 0.01). Plasma metformin concentra-
tions showed a signiﬁcant time by exer-
cise interaction (P =0 . 0 5 )d u r i n gt h e2 - h
postmeal period, with metformin con-
centration becoming similar near the
end of the 2-h period.
Plasma glucose, lactate, NEFAs,
insulin, and glucagon
Fasting glucose was lower in the met-
formin condition compared with the pla-
cebo condition (6.4 6 0.6 vs. 7.2 6 0.6
mmol/L;P=0.02).AsshowninFig.1,the
mean glucose concentration continued
to be lower throughout the day in the
metformin conditions compared with
placebo, with the difference becoming
statistically signiﬁcant after exercise. Ac-
cording to the sample taken immediately
before lunch, exercise lowered plasma
glucose concentration in the placebo
condition but not in the metformin con-
dition(21.162.0vs.0.161.1mmol/L,
respectively); however, the metformin 3
exercise interaction was not signiﬁcant
(P = 0.17). The metformin 3 exercise in-
teraction reached statistical signiﬁcance
during the 2-h postlunch period (P =
0.05), suggesting that exercise caused an
increased glycemic response in the met-
formin condition but not in the placebo
condition.
Throughout the entire sessions, lac-
tate concentrations were higher in the
metformin condition compared with pla-
cebo (all P # 0.05). Lactate concentra-
tions increased with increasing exercise
intensity and remained elevated for 20
min after exercise (both P , 0.01).
NEFA concentrations were also increased
after exercise (P , 0.01).
Insulin concentrations were lowered
by exercise but were similar in the met-
forminversusplaceboconditions through-
out the day with the exception of higher
insulin concentrations after lunch in the
placebo condition (P , 0.01). Glucagon
concentrations were increased in the
metformin conditions (all P , 0.01).
Potential confounding variables
T h e r ew e r en os i g n i ﬁcant differences in
total calorie intake (1,906 6 293 vs.
1,978 6 518 kcal; P =0 . 5 1 )o rd i s t r i -
bution of macronutrients in the 24 h
preceding the testing sessions (all P .
0.52). There was no difference in the
amount of physical activity completed
during the metformin versus placebo
conditions (Godin Leisure Time Ques-
tionnaire score 36 6 21 vs. 52 6 36;
P = 0.13). Participants did not report ex-
periencing any difference in symptoms
such as abdominal discomfort between
conditions. Participants rated a higher
likelihood of taking metformin while
they were in the metformin condition
compared with placebo (89 6 40 mm
vs. 62 6 47 mm on the 150-mm visual
Table 1—Participant characteristics
Baseline
Sex (men/postmenopausal
women) 8/2
Age (years) 58 6 6
BMI (kg/m
2) 28.6 6 5.3
Weight (kg) 86.9 6 18.7
A1C (%) 6.5 6 0.6
Fasting glucose (mmol/L) 7.3 6 0.6
VO2peak (mL z kg
21 z min
21) 30.2 6 5.1
Data are reported as mean 6 SD.
Table 2—Effect of metformin on exercise-related outcomes
Metformin Placebo
Metformin
vs. placebo
conditions
Low vs.
moderate vs.
vigorous
intensity
Interaction
(condition 3
intensity)
Treadmill exercise
VO2 (mL z min
21 z kg
21) P =0 . 6 0 P , 0.01 P = 0.18
Low intensity 10.09 6 1.01 10.01 6 1.62
Moderate intensity 20.45 6 3.69 20.02 6 3.74
Vigorous intensity 23.95 6 4.01 23.81 6 4.37
RER P =0 . 0 3 P , 0.01 P = 0.38
Low intensity 0.92 6 0.06 0.95 6 0.08
Moderate intensity 0.96 6 0.03 0.97 6 0.03
Vigorous intensity 0.99 6 0.08 1.02 6 0.07
HR (bpm) P =0 . 0 1 P , 0.01 P = 0.23
Low intensity 97 6 12 91 6 13
Moderate intensity 132 6 21 126 6 19
Vigorous intensity 142 6 24 138 6 21
RPE (Borg) P =0 . 0 3 P , 0.01 P = 0.62
Low intensity 8 6 18 6 1
Moderate intensity 13 6 11 3 6 1
Vigorous intensity 14 6 11 3 6 1
Isokinetic strength
Peak torque 70 6 25 74 6 26 P =0 . 1 3 ——
Mean torque 58 6 21 60 6 23 P =0 . 1 2 ——
Fatigue index 33 6 10 36 6 11 P =0 . 3 2 ——
Data are reported as mean 6 SD. RER is in VCO2/VO2; RPE is on a scale of 6–20. Analyses were adjusted for
treatment order (i.e., metformin ﬁrst vs. placebo ﬁrst).
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Boulé and Associatesanalog scale), but the difference did not
reach statistical signiﬁcance (P =0 . 2 0 ) .
Body mass was similar after the 28-day
placebo condition versus after the 28-
day metformin condition (86.7 6 19.0
vs. 86.7 6 18.9 kg; P = 0.93).
CONCLUSIONS—In the 1960s and
1970s several studies had investigated
the effect of metformin on exercise per-
formance because of concerns over lactic
acidosis (see reference 13 for a detailed
review). Although the combination of
metformin and exercise was perceived as
safe, interest in this area has reemerged
in recent years (4,7,14,15). The current
study is unique in that it focused on
continuous exercise at several submaxi-
mal intensities that are relevant to activity
patterns of people with type 2 diabetes
and that we examined the interaction be-
tween exercise and metformin on the gly-
cemic and hormonal responses to a
subsequent meal.
We found that metformin increased
lipid oxidation as evidenced by a lower
RER during all three submaximal inten-
sitiesofexercise.Accordingtononprotein
RER tables, this would correspond to an
increased lipid oxidation from 16 to 26%
oftotalenergyexpenditurewhenwalking
at 3.5 km/h. Increased lipid oxidation is
considered a normal adaption to exercise
training. However, metformin increased
submaximal HR and lactate concentra-
tions, which are opposite to the direction
of changes expected with regular exercise
training. In the current study, HR was
increased by a mean of 6 bpm. Interest-
ingly, Sharoff et al. (4) also found an
increased HR of about 8 and 5 bpm dur-
ing exercise at 65 and 85% of VO2peak,r e -
spectively; however, in their study the
increase in HR did not reach statistical
signiﬁcance. In our study, a higher rating
o fp e r c e i v e de x e r t i o ni nt h em e t f o r m i n
condition was also observed, although
participants were all able to complete
the exercise bouts. Taken together, this
suggests that metformin has the potential
to lower some patients’ selected exercise
intensity since perceived exertion and HR
are common feedback modalities and are
frequently used to prescribe exercise in-
tensities.
Although statistical signiﬁcance was
not reached, peak and mean torque for
knee extension were lower in the metfor-
min condition. Lower mean torque may
have been expected based on the reduced
muscle ATP concentrations observed by
week 4 of metformin treatment in the
study by Musi et al. (16).
Maximal metformin concentrations
are typically reached 120–240 min after
a dose. In the current study, we observed
greaterplasmametforminconcentrations
25 min before exercise and 20 min after
exercise compared with samples taken at
the same times on the rest day (150 and
225 min postdose). The reasons for
thesehigherconcentrationsareunknown
but may have been caused by the antici-
patory and stress responses to exercise,
w h i c ha r ek n o w nt oi n c r e a s eH Ra n d
blood pressure while redistributing
blood ﬂow to tissues such as skeletal
muscle (17). Hence, the alteration in
blood ﬂow may have caused a transient
decrease in the distribution of drug to cer-
tain tissues, including the liver. Indeed,
this may have contributed to the reduced
hypoglycemic effect of metformin after
exercise even though plasma concentra-
tions were higher at some time points. A
reduced renal blood ﬂow could increase
plasma concentrations of drugs such as
metformin, which are primarily elimi-
nated by the kidneys (18). This may
have also contributed to some of the
higher concentrations measured inthe ex-
ercise group, although only a more com-
plete assessment of plasma metformin
concentrations and urinary recovery
could answer this question. A limitation
of the current study is that the three blood
Figure 1—Data are reported as mean 6 SD (except for insulin: mean 6 SEM). Analyses were
adjusted for treatment order (i.e., metformin ﬁrst vs. placebo ﬁrst). N =9o r1 0 .N A ,n o ta p p l i -
cable; Mod, moderate; Vig, vigorous; Ex, exercise. ●, metformin + no exercise; ■, metformin +
exercise; ○,p l a c e b o+n oe x e r c i s e ;□, placebo + exercise. *Effect of exercise; †effect of time;
‡effect of metformin; §exercise by metformin interaction; ||exercise by time interaction; ¶met-
formin by time interaction.
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Metformin and exercisesamples taken immediately after each aer-
obic exercise bout were not taken at the
corresponding times on the nonexercise
days.
Although some previous studies had
suggested that the effects of exercise and
metformin on insulin sensitivity (4) or on
the risk of diabetes (3) are not additive,
our results suggest that in some condi-
tions the combination may in fact be less
effective at lowering the glycemic re-
sponse to a meal than metformin alone.
The reasonsfor this arenot clear,butmay
be related to the strong counterregulatory
response when the two were combined.
Inourstudy,theglucagonconcentrations
peaked immediately before lunch and
were highest in the combined metformin
and exercise condition. In support of the
notion that glucose production may have
been increased by the higher glucagon
concentrations, Sharoff et al. (4) showed
that hepatic glucose production was in-
creased 2 h afterexercisewithmetformin,
unchanged by metformin alone, and de-
creased by exercise alone (4). Important
differencesbetweenourstudyandSharoff
et al. (4) are that in the latter study par-
ticipants were nondiabetic and 2 to 3
weeks of metformin use did not appear
to alter insulin sensitivity or resting glu-
cose concentration. Nonetheless, taken
together these studies provide interesting
insight on glucose homeostasis after met-
formin and exercise.
The lack of improvement in postmeal
(lunch) plasma glucose concentrations
on the exercise days should not discour-
age the use of exercise as a treatment
modality. Rather, this study emphasizes
that it may be important to further con-
sider the timing of exercise and meals
to obtain optimal glycemic beneﬁts. For
example, others have shown that exercis-
ing in the fasting state (a condition that
also leads to pronounced counterregula-
tory responses) was much less effective at
lowering plasma glucose than was exer-
cising after a meal (19,20).
Furthermore, it is important to re-
member that the exercise protocol in
the current study ended with 5 min of
exercise at an intensity above ventila-
tory threshold. Similarly, in the study by
Sharoff et al. (4), the exercise protocol
e n d e dw i t h1 0m i na t8 5 %o fVO2peak.
High intensity exercise (i.e., above venti-
latory threshold) in the postabsorptive
state is known to cause an increase in
counterregulatory hormones and glucose
in type 2 diabetes (21). However, high
intensity exercise performed 45 min after
the beginning of breakfast led to a de-
creased glycemic response to a meal
that was provided 2.5 h after exercise
(22). It would be of interest to examine
if interactions between metformin and
exercise on glucose homeostasis would
be as pronounced after lower intensity
exercise.
Type 2 diabetes is characterized not
only by insulin deﬁciency but also by
hyperglucagonemia(23).Weare aware of
nonexercise studies that have suggested
that metformin may increase glucagon
concentrations, but the increases were
not statistically signiﬁcant (24,25). In
the nonrandomized exercise studies by
Cunha et al. (14,15), glucagon concen-
trations were signiﬁcantly higher in the
participants with type 2 diabetes taking
metformin compared with those taking
glibenclamide or those with normal glu-
cose tolerance. Although speculative, the
glucose-lowering beneﬁts of metformin
could be further enhanced by strategies
that could help minimize the exercise-
induced increased glucagon levels such
as exercising after a meal.
In conclusion, our study reports sev-
eral novel ﬁndings regarding the con-
comitant use of metformin and exercise,
speciﬁcally: 1) increased HR during exer-
cise with metformin, 2) higher plasma
metformin concentrations with exercise,
and 3) nonadditive effects of metformin
and exercise on the glycemic response to
feeding. In our opinion, the magnitudes
of these effects were small but have the
potential to reduce the effectiveness of
this therapeutic combination in diabetes
treatment.Additionalresearch couldhelp
optimize the concurrent use of these im-
portant and widely prescribed treatment
modalities for diabetes.
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